
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Amicus Therapeutics Inc (FOLD)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: FOLD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $16.09
1 Year Target Price $16.09
8 | Strong Buy |
1 | Buy |
3 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22.21% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.35B USD | Price to earnings Ratio - | 1Y Target Price 16.09 |
Price to earnings Ratio - | 1Y Target Price 16.09 | ||
Volume (30-day avg) 12 | Beta 0.53 | 52 Weeks Range 5.51 - 12.65 | Updated Date 08/24/2025 |
52 Weeks Range 5.51 - 12.65 | Updated Date 08/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.12 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-31 | When - | Estimate -0.11 | Actual 0.01 |
Profitability
Profit Margin -6.67% | Operating Margin (TTM) -5.02% |
Management Effectiveness
Return on Assets (TTM) 2% | Return on Equity (TTM) -22.62% |
Valuation
Trailing PE - | Forward PE 285.71 | Enterprise Value 2558018636 | Price to Sales(TTM) 4.11 |
Enterprise Value 2558018636 | Price to Sales(TTM) 4.11 | ||
Enterprise Value to Revenue 4.48 | Enterprise Value to EBITDA 77.37 | Shares Outstanding 308239008 | Shares Floating 288206897 |
Shares Outstanding 308239008 | Shares Floating 288206897 | ||
Percent Insiders 0.72 | Percent Institutions 104.75 |
Upturn AI SWOT
Amicus Therapeutics Inc

Company Overview
History and Background
Amicus Therapeutics Inc. was founded in 2002. It is a global biotechnology company focused on discovering, developing, and delivering medicines for rare diseases.
Core Business Areas
- Global Pompe: Development and commercialization of therapies for Pompe disease, including AT-GAA (cipaglucosidase alfa and miglustat) now known as Pombiliti + Opfolda. These therapies are the primary revenue drivers of the company.
- Chaperone Technology: Developing pharmacological chaperones to treat a variety of genetic diseases by stabilizing misfolded proteins.
- Gene Therapy: Researching and developing gene therapies for other rare diseases including CLN6 Batten disease.
Leadership and Structure
John F. Crowley is the Chairman and Chief Executive Officer. The company has a typical biotechnology organizational structure with research, development, commercial, and administrative functions.
Top Products and Market Share
Key Offerings
- Pombiliti + Opfolda: A two-component therapy (cipaglucosidase alfa and miglustat) for late-onset Pompe disease (LOPD). Launched in the US in May 2024, and previously launched in the UK and EU. The primary competitor is Nexviazyme (avalglucosidase alfa) from Sanofi. Market share data is still evolving with initial launch. This is the primary revenue driver for Amicus and expected to drive growth for the next 10 years.
- Galafold (migalastat): An oral pharmacological chaperone approved for Fabry disease in patients with amenable mutations. Competitors include enzyme replacement therapies (ERTs) like Fabrazyme (Sanofi) and Replagal (Takeda). Galafold has a significant share of the Fabry market within the amenable mutation subset, however this is slowly being eroded by ERTs due to their wider patient label.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, long regulatory pathways, and significant competition. The rare disease market is a growing segment due to unmet medical needs and regulatory incentives.
Positioning
Amicus Therapeutics Inc. focuses on rare diseases, giving it a niche position. The company's strength lies in its expertise in protein folding and chaperone technology. However, its dependence on a few key products makes it vulnerable to competition.
Total Addressable Market (TAM)
The total addressable market for Pompe disease and Fabry disease combined is estimated to be several billion dollars annually. Amicus is positioned to capture a significant portion of this TAM with its approved therapies.
Upturn SWOT Analysis
Strengths
- Approved therapies for Pompe and Fabry diseases
- Strong expertise in protein folding and chaperone technology
- Established commercial infrastructure in key markets
- Deep pipeline of potential therapies
Weaknesses
- High dependence on a limited number of products
- Intense competition in the rare disease market
- Significant debt burden
- Regulatory and reimbursement risks
Opportunities
- Expansion into new markets and indications
- Advancement of pipeline programs
- Strategic partnerships and acquisitions
- Increased awareness and diagnosis of rare diseases
Threats
- Competition from established pharmaceutical companies
- Patent expirations
- Adverse regulatory decisions
- Economic downturn
Competitors and Market Share
Key Competitors
- SNY
- TAK
Competitive Landscape
Amicus has a competitive advantage in certain rare disease markets due to its focus on pharmacological chaperones and gene therapies. However, larger pharmaceutical companies with greater resources pose a significant threat. Sanofi (SNY) and Takeda (TAK) are significant competitors with established products and infrastructure.
Major Acquisitions
Callidus Biopharma
- Year: 2017
- Acquisition Price (USD millions): 130
- Strategic Rationale: Expanded Amicus' pipeline into gene therapy for rare diseases.
Growth Trajectory and Initiatives
Historical Growth: Revenue growth has been driven by sales of Galafold and more recently, Pombiliti + Opfolda. The company has invested heavily in research and development to expand its pipeline.
Future Projections: Analysts predict continued revenue growth driven by Pombiliti + Opfolda and potential new product launches. Profitability is expected to improve as the company scales its operations.
Recent Initiatives: The launch of Pombiliti + Opfolda for Pompe disease, advancement of gene therapy programs, and expansion into new markets.
Summary
Amicus Therapeutics is a biotechnology company specializing in rare diseases, demonstrating promise with therapies like Pombiliti + Opfolda. High R&D costs contribute to net losses, while revenue growth depends on successful product launches. Competition from larger companies and regulatory risks remain threats. Focusing on pipeline development and strategic partnerships is crucial for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amicus Therapeutics Inc
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2007-05-31 | CEO, President & Director Mr. Bradley L. Campbell M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 499 | Website https://amicusrx.com |
Full time employees 499 | Website https://amicusrx.com |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.